Cargando…

Imatinib Responsiveness in Canine Mast Cell Tumors Carrying Novel Mutations of c-KIT Exon 11

In 2 individual cases of canine mast cell tumors, we identified 2 novel c-KIT mutations in exon 11: a 9-base pair (bp) deletion (c.1663-1671del) and a point mutation (c.1676T>A). The 9-bp deletion mutation caused a loss of 3 amino acids, corresponding to p.Gln555_Lys557del, and the point mutation...

Descripción completa

Detalles Bibliográficos
Autores principales:	NAKANO, Yuko, KOBAYASHI, Tetsuya, OSHIMA, Fukiko, FUKAZAWA, Eri, YAMAGAMI, Tetsushi, SHIRAISHI, Yozo, TAKANOSU, Masamine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Veterinary Science 2013
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064139/ https://www.ncbi.nlm.nih.gov/pubmed/24292246 http://dx.doi.org/10.1292/jvms.13-0156

Ejemplares similares

The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs
por: Gentilini, Fabio, et al.
Publicado: (2020)

Mutations in C-KIT exon 11 in canine cutaneous mast cell tumors
por: Neto, Rafael T, et al.
Publicado: (2013)

Clinical features and prognosis of retroperitoneal hemangiosarcoma in dogs with surgical resection with or without adjuvant doxorubicin
por: ICHIMATA, Masanao, et al.
Publicado: (2023)

Evaluation of adverse events in small‐breed dogs treated with maropitant and a single dose of doxorubicin
por: Matsuyama, Fukiko, et al.
Publicado: (2022)

Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H
por: Revheim, Mona-Elisabeth, et al.
Publicado: (2013)

Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation
por: IRIE, Mitsuhiro, et al.
Publicado: (2015)

Long-term survival in a dog with primary hepatic neuroendocrine tumor treated with toceranib phosphate
por: ICHIMATA, Masanao, et al.
Publicado: (2021)

Mutations in Exons 8 and 11 of c-kit Gene in Canine Subcutaneous Mast Cell Tumors and Their Association with Cell Proliferation
por: Chen, Polly, et al.
Publicado: (2022)

Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I
por: Orlova, Kristina V., et al.
Publicado: (2019)

Different allelic frequency of progressive rod-cone degeneration in two populations of Labrador Retrievers in Japan
por: TAKANOSU, Masamine
Publicado: (2017)

Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors
por: Webster, Joshua D, et al.
Publicado: (2006)

Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report
por: Engin, Gulgun, et al.
Publicado: (2017)

Prognosis of primary pulmonary adenocarcinoma after surgical resection in small‐breed dogs: 52 cases (2005‐2021)
por: Ichimata, Masanao, et al.
Publicado: (2023)

Genotype frequency of ATP7A and ATP7B mutation-related copper-associated hepatitis in a Japanese guide dog Labrador retriever population
por: TAKANOSU, Masamine, et al.
Publicado: (2021)

Osteochondrodysplasia in Scottish Fold cross-breed cats
por: TAKANOSU, Masamine, et al.
Publicado: (2020)

The exon-skipping oligonucleotide, KitStop, depletes tissue-resident mast cells in vivo to ameliorate anaphylaxis
por: Hedgespeth, Barry A., et al.
Publicado: (2023)

A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis
por: Kurtz, Jean-Emmanuel, et al.
Publicado: (2010)

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma
por: Zukotynski, Katherine, et al.
Publicado: (2014)

The Relevance of CD117-Immunocytochemistry Staining Patterns to Mutational Exon-11 in c-kit Detected by PCR from Fine-Needle Aspirated Canine Mast Cell Tumor Cells
por: Sailasuta, A., et al.
Publicado: (2014)

Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11
por: Gregory-Bryson, Emmalena, et al.
Publicado: (2010)

Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature
por: Alvarez-Twose, Iván, et al.
Publicado: (2016)

Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report
por: Malik, Faizan, et al.
Publicado: (2017)

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
por: Vincenzi, Bruno, et al.
Publicado: (2022)

C-Kit Expression, Angiogenesis, and Grading in Canine Mast Cell Tumour: A Unique Model to Study C-Kit Driven Human Malignancies
por: Patruno, Rosa, et al.
Publicado: (2014)

The role of c-kit and imatinib mesylate in uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2005)

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E
por: Catania, Chiara, et al.
Publicado: (2014)

Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon
por: Incorvaia, Lorena, et al.
Publicado: (2021)

Concordance of c‐kit Mutational Status in Matched Primary and Metastatic Cutaneous Canine Mast Cell Tumors at Baseline
por: Marconato, L., et al.
Publicado: (2013)

Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone
por: Macedo, Thais Rodrigues, et al.
Publicado: (2022)

Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations
por: Miyake, Kentaro, et al.
Publicado: (2018)

Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)
por: Spitaleri, Gianluca, et al.
Publicado: (2015)

RNAScope in situ Hybridization as a Novel Technique for the Assessment of c-KIT mRNA Expression in Canine Mast Cell Tumor
por: De Biase, Davide, et al.
Publicado: (2021)

Inhibition of c-Kit Is Not Required for Reversal of Hyperglycemia by Imatinib in NOD Mice
por: Lau, Janet, et al.
Publicado: (2014)

TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
por: Saito, Yurina, et al.
Publicado: (2019)

Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2019)

Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology
por: Dufresne, Armelle, et al.
Publicado: (2014)

Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients
por: Mohammadi, Mahmoud, et al.
Publicado: (2022)

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
por: Handolias, D, et al.
Publicado: (2010)

Sustained response to imatinib in patient with extraskeletal myxoid chondrosarcoma and novel KIT mutation
por: Jennings, Brooke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sfqle7bpo1d2mdpg15baodulml